Seres Therapeutics Company Profile (NASDAQ:MCRB)

About Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics logoSeres Therapeutics, Inc. is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company's drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. SER-109 is its lead product candidate, which is designed to prevent further recurrences of Clostridium difficile infection (CDI). The Company is developing additional product candidates, including SER-262 to prevent an initial recurrence of primary CDI; SER-287 and SER-301, to treat inflammatory bowel disease (IBD), including ulcerative colitis, and SER-155 to treat enteric bacterial pathogens.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $378.86 million
  • Outstanding Shares: 40,390,000
Average Prices:
  • 50 Day Moving Avg: $9.99
  • 200 Day Moving Avg: $10.23
  • 52 Week Range: $8.05 - $35.98
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.27
  • P/E Growth: -0.07
Sales & Book Value:
  • Annual Revenue: $22.07 million
  • Price / Sales: 17.17
  • Book Value: $2.76 per share
  • Price / Book: 3.40
Profitability:
  • EBIDTA: ($93,260,000.00)
  • Return on Equity: -47.97%
  • Return on Assets: -30.02%
Debt:
  • Debt-to-Equity Ratio: 0.07%
  • Current Ratio: 6.54%
  • Quick Ratio: 6.54%
Misc:
  • Average Volume: 241,706 shs.
  • Beta: 0.3
  • Short Ratio: 22.53
 

Frequently Asked Questions for Seres Therapeutics (NASDAQ:MCRB)

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics Inc (NASDAQ:MCRB) announced its earnings results on Thursday, May, 4th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.65) by $0.02. The business had revenue of $3.02 million for the quarter, compared to analyst estimates of $3 million. The business's revenue was up 11.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.50) EPS. View Seres Therapeutics' Earnings History.

Where is Seres Therapeutics' stock going? Where will Seres Therapeutics' stock price be in 2017?

7 brokerages have issued 12-month price objectives for Seres Therapeutics' stock. Their predictions range from $12.00 to $50.00. On average, they anticipate Seres Therapeutics' share price to reach $23.20 in the next year. View Analyst Ratings for Seres Therapeutics.

What are analysts saying about Seres Therapeutics stock?

Here are some recent quotes from research analysts about Seres Therapeutics stock:

  • 1. Cowen and Company analysts commented, "We are optimistic that modifications to the clinical trial plan for SER-109 in recurrent." (5/19/2017)
  • 2. According to Zacks Investment Research, "Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/2/2017)
  • 3. Canaccord Genuity analysts commented, "We believe that SER-109 Phase 2 trial study power was decreased by the inclusion of misdiagnosed and non-disease active patients. MCRB indicated that 72 of the 89 patients enrolled in the Phase 2 trials were chosen based on C. Difficile PCR diagnosis. A positive PCR test indicates that the cytotoxin gene is present, but does not directly indicate that the C. Difficile bacterium is producing the cytotoxin that causes the underlying symptoms. Thus a direct testing of cytotoxin is the most indicative of disease activity, and further qualifying stool samples analysis showed that only 15 of 31 PCR- positive samples were cytotoxin-positive. Importantly, Optimer utilized toxin testing for its fidaxomicin clinical program for recurrent C." (1/31/2017)

Are investors shorting Seres Therapeutics?

Seres Therapeutics saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 3,106,958 shares, an increase of 14.2% from the April 13th total of 2,721,263 shares. Based on an average trading volume of 167,842 shares, the days-to-cover ratio is currently 18.5 days.

Who are some of Seres Therapeutics' key competitors?

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the folowing people:

  • Roger Pomerantz M.D., Chairman of the Board, President, Chief Executive Officer
  • David A. Berry M.D., Ph.D., Co-Founder, Director
  • Eric D. Shaff, Chief Financial Officer, Executive Vice President
  • John G. Aunins Ph.D., Chief Technology Officer, Executive Vice President - Bioprocess and Manufacturing
  • David N. Cook Ph.D., Chief Scientific Officer, Executive Vice President - Research & Development
  • Wael Hashad, Chief Commercial Officer, Executive Vice President
  • Michele Trucksis Ph.D. M.D., Chief Medical Officer and Executive Vice President
  • Noubar B. Afeyan Ph.D., Director
  • Dennis A. Ausiello M.D., Director
  • Gregory Behar, Director

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering (IPO) on Friday, June 26th 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

Who owns Seres Therapeutics stock?

Seres Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Flagship Pioneering Inc. (31.42%), FMR LLC (14.99%), Vanguard Group Inc. (3.88%), JPMorgan Chase & Co. (0.92%), Renaissance Technologies LLC (0.87%) and Wellington Management Group LLP (0.46%). Company insiders that own Seres Therapeutics stock include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis, Roger Pomerantz and Ventures Fund 2007 L Flagship. View Institutional Ownership Trends for Seres Therapeutics.

Who sold Seres Therapeutics stock? Who is selling Seres Therapeutics stock?

Seres Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Renaissance Technologies LLC, Morgan Stanley, Oxford Asset Management, Wellington Management Group LLP, ProShare Advisors LLC, Teachers Advisors LLC and TD Asset Management Inc.. Company insiders that have sold Seres Therapeutics stock in the last year include David N Cook, Eric D Shaff, John G Aunins, Michele Trucksis and Roger Pomerantz. View Insider Buying and Selling for Seres Therapeutics.

Who bought Seres Therapeutics stock? Who is buying Seres Therapeutics stock?

Seres Therapeutics' stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Spark Investment Management LLC, JPMorgan Chase & Co., American Century Companies Inc., Tudor Investment Corp ET AL, Dimensional Fund Advisors LP, Highbridge Capital Management LLC and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Seres Therapeutics.

How do I buy Seres Therapeutics stock?

Shares of Seres Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Seres Therapeutics' stock price today?

One share of Seres Therapeutics stock can currently be purchased for approximately $9.38.


MarketBeat Community Rating for Seres Therapeutics (NASDAQ MCRB)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  84 (Vote Underperform)
Total Votes:  192
MarketBeat's community ratings are surveys of what our community members think about Seres Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Seres Therapeutics (NASDAQ:MCRB) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $23.20 (147.33% upside)

Analysts' Ratings History for Seres Therapeutics (NASDAQ:MCRB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017Cowen and CompanyReiterated RatingBuyMediumView Rating Details
5/4/2017Cantor FitzgeraldSet Price TargetBuy$16.00HighView Rating Details
5/4/2017Canaccord GenuitySet Price TargetBuy$20.00HighView Rating Details
3/20/2017FBR & CoReiterated RatingOutperform$18.00LowView Rating Details
8/11/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
8/1/2016Bank of America CorpDowngradeBuy -> NeutralN/AView Rating Details
7/29/2016HC WainwrightInitiated CoverageBuy$50.00N/AView Rating Details
3/3/2016GuggenheimInitiated CoverageBuy$41.00N/AView Rating Details
2/22/2016Goldman Sachs Group IncLower Price Target$35.00 -> $34.00N/AView Rating Details
(Data available from 5/30/2015 forward)

Earnings

Earnings History for Seres Therapeutics (NASDAQ:MCRB)
Earnings by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Earnings History by Quarter for Seres Therapeutics (NASDAQ MCRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.65)($0.63)$3.00 million$3.02 millionViewListenView Earnings Details
3/16/2017Q4 2016($0.70)($0.63)$3.00 million$3.00 millionViewN/AView Earnings Details
11/10/2016Q316($0.55)($0.46)$10.38 million$13.02 millionViewListenView Earnings Details
8/11/2016Q216($0.46)($0.70)$4.20 million$3.00 millionViewListenView Earnings Details
5/16/2016Q116($0.48)($0.50)$1.25 million$2.71 millionViewListenView Earnings Details
11/10/2015Q315($0.32)($0.38)ViewListenView Earnings Details
8/6/2015Q215($0.30)($1.45)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Seres Therapeutics (NASDAQ:MCRB)
2017 EPS Consensus Estimate: ($2.60)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.73)($0.53)($0.63)
Q2 20172($0.61)($0.50)($0.56)
Q3 20172($0.74)($0.66)($0.70)
Q4 20172($0.75)($0.68)($0.72)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Seres Therapeutics (NASDAQ:MCRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Seres Therapeutics (NASDAQ:MCRB)
Insider Ownership Percentage: 41.90%
Institutional Ownership Percentage: 77.62%
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Institutional Ownership by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Insider Trades by Quarter for Seres Therapeutics (NASDAQ:MCRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/29/2016John G AuninsInsiderSell9,390$10.87$102,069.30View SEC Filing  
7/28/2016Michele TrucksisInsiderSell4,156$35.18$146,208.08View SEC Filing  
7/27/2016Michele TrucksisInsiderSell38,064$35.14$1,337,568.96View SEC Filing  
7/25/2016John G AuninsInsiderSell9,390$34.18$320,950.20View SEC Filing  
7/6/2016Roger PomerantzCEOSell88,211$29.45$2,597,813.95View SEC Filing  
7/1/2016Roger PomerantzCEOSell56,789$29.81$1,692,880.09View SEC Filing  
6/30/2016Eric D ShaffCFOSell4,533$29.54$133,904.82View SEC Filing  
6/28/2016Eric D ShaffCFOSell5,001$28.28$141,428.28View SEC Filing  
6/27/2016John G AuninsEVPSell9,390$27.23$255,689.70View SEC Filing  
6/2/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
6/2/2016Roger PomerantzCEOSell74,049$32.52$2,408,073.48View SEC Filing  
6/1/2016David N CookEVPSell16,000$29.43$470,880.00View SEC Filing  
6/1/2016Roger PomerantzCEOSell70,951$30.51$2,164,715.01View SEC Filing  
5/25/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell1,000,000$27.60$27,600,000.00View SEC Filing  
5/24/2016Roger PomerantzCEOSell9,801$30.00$294,030.00View SEC Filing  
5/6/2016Roger PomerantzCEOSell8,507$24.31$206,805.17View SEC Filing  
5/5/2016Roger PomerantzCEOSell59,325$26.13$1,550,162.25View SEC Filing  
5/3/2016Roger PomerantzCEOSell67,367$28.70$1,933,432.90View SEC Filing  
4/25/2016John G AuninsEVPSell18,640$31.94$595,361.60View SEC Filing  
4/7/2016David N CookEVPSell8,000$31.00$248,000.00View SEC Filing  
4/7/2016Roger PomerantzCEOSell9,212$30.00$276,360.00View SEC Filing  
4/4/2016David N CookEVPSell61,000$26.16$1,595,760.00View SEC Filing  
4/4/2016Eric D ShaffCFOSell6,568$28.85$189,486.80View SEC Filing  
4/4/2016Roger PomerantzCEOSell135,788$27.20$3,693,433.60View SEC Filing  
3/31/2016Eric D ShaffCFOSell7,663$26.30$201,536.90View SEC Filing  
3/28/2016Eric D ShaffCFOSell5,473$24.07$131,735.11View SEC Filing  
3/28/2016John G AuninsEVPSell9,390$23.89$224,327.10View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Seres Therapeutics (NASDAQ:MCRB)
Latest Headlines for Seres Therapeutics (NASDAQ:MCRB)
Source:
DateHeadline
americanbankingnews.com logoShort Interest in Seres Therapeutics Inc (MCRB) Grows By 14.2%
www.americanbankingnews.com - May 22 at 2:46 PM
americanbankingnews.com logoCowen and Company Reaffirms "Buy" Rating for Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - May 19 at 11:34 AM
americanbankingnews.com logoBrokers Issue Forecasts for Seres Therapeutics Inc's FY2017 Earnings (MCRB)
www.americanbankingnews.com - May 12 at 12:33 PM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) PT Set at $20.00 by Canaccord Genuity
www.americanbankingnews.com - May 7 at 8:03 AM
americanbankingnews.com logoCantor Fitzgerald Analysts Give Seres Therapeutics Inc (MCRB) a $16.00 Price Target
www.americanbankingnews.com - May 7 at 7:42 AM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Releases Earnings Results, Beats Expectations By $0.02 EPS
www.americanbankingnews.com - May 5 at 10:22 PM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 5 at 9:08 PM
finance.yahoo.com logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : MCRB-US : May 5, 2017
finance.yahoo.com - May 5 at 6:44 PM
finance.yahoo.com logoEdited Transcript of MCRB earnings conference call or presentation 4-May-17 12:00pm GMT
finance.yahoo.com - May 4 at 11:34 PM
finance.yahoo.com logoSeres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress - Yahoo Finance
finance.yahoo.com - May 4 at 6:33 PM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Releases Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - May 4 at 4:56 PM
finance.yahoo.com logoSeres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress
finance.yahoo.com - May 4 at 11:45 AM
finance.yahoo.com logoSeres Therapeutics reports 1Q loss
finance.yahoo.com - May 4 at 11:45 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Seres Therapeutics Inc (MCRB) Will Post Earnings of -$0.65 Per Share
www.americanbankingnews.com - May 4 at 1:05 AM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Expected to Announce Quarterly Sales of $3 Million
www.americanbankingnews.com - May 4 at 1:05 AM
americanbankingnews.com logoSeres Therapeutics (MCRB) Getting Somewhat Favorable Media Coverage, Analysis Shows
www.americanbankingnews.com - May 3 at 2:39 PM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Set to Announce Earnings on Thursday
www.americanbankingnews.com - May 2 at 10:14 PM
americanbankingnews.com logo$3 Million in Sales Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - April 30 at 9:36 AM
americanbankingnews.com logoSeres Therapeutics (MCRB) Receives Media Impact Score of 0.04
www.americanbankingnews.com - April 30 at 8:28 AM
finance.yahoo.com logoSeres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and ... - Yahoo Finance
finance.yahoo.com - April 29 at 12:23 AM
finance.yahoo.com logoSeres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017
finance.yahoo.com - April 28 at 7:21 PM
americanbankingnews.com logoZacks: Brokerages Expect Seres Therapeutics Inc (MCRB) Will Post Earnings of -$0.65 Per Share
www.americanbankingnews.com - April 28 at 9:08 AM
americanbankingnews.com logoSeres Therapeutics (MCRB) Earns Daily Coverage Optimism Rating of 0.14
www.americanbankingnews.com - April 28 at 12:22 AM
americanbankingnews.com logoSeres Therapeutics (MCRB) Earning Somewhat Negative Press Coverage, Report Finds
www.americanbankingnews.com - April 23 at 3:13 PM
americanbankingnews.com logoSeres Therapeutics (MCRB) Getting Favorable Press Coverage, Analysis Shows
www.americanbankingnews.com - April 21 at 12:13 AM
finance.yahoo.com logoSeres Therapeutics, Inc. – Value Analysis (NASDAQ:MCRB) : April 19, 2017
finance.yahoo.com - April 19 at 6:32 PM
finance.yahoo.com logoSeres Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : MCRB-US : April 18, 2017
finance.yahoo.com - April 18 at 10:30 AM
americanbankingnews.com logoSeres Therapeutics (MCRB) Receiving Somewhat Favorable Media Coverage, Report Finds
www.americanbankingnews.com - April 15 at 2:55 PM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 10 at 8:51 PM
americanbankingnews.com logo-$0.65 EPS Expected for Seres Therapeutics Inc (MCRB) This Quarter
www.americanbankingnews.com - April 7 at 8:21 PM
americanbankingnews.com logoQ1 2017 Earnings Forecast for Seres Therapeutics Inc Issued By FBR & Co (MCRB)
www.americanbankingnews.com - March 23 at 9:56 AM
americanbankingnews.com logoSeres Therapeutics Inc Expected to Post FY2017 Earnings of ($2.75) Per Share (MCRB)
www.americanbankingnews.com - March 23 at 9:56 AM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Earns Overweight Rating from Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 8:53 AM
finance.yahoo.com logoSERES THERAPEUTICS, INC. Financials
finance.yahoo.com - March 22 at 6:36 PM
americanbankingnews.com logoFBR & Co Reaffirms Outperform Rating for Seres Therapeutics Inc (MCRB)
www.americanbankingnews.com - March 20 at 2:25 PM
rttnews.com logoSeres Therapeutics Inc. (MCRB) Surged To A 4-Month High
www.rttnews.com - March 17 at 9:02 AM
finance.yahoo.com logoEdited Transcript of MCRB earnings conference call or presentation 16-Mar-17 12:00pm GMT
finance.yahoo.com - March 17 at 9:02 AM
finanznachrichten.de logoGainers & Losers Of Mar.16: MCRB, PLSE, OCUL, PTCT, TROV...
www.finanznachrichten.de - March 17 at 12:13 AM
us.rd.yahoo.com logoSeres Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Operational Progress Update
us.rd.yahoo.com - March 17 at 12:13 AM
us.rd.yahoo.com logoSeres Therapeutics to Initiate New SER-109 Clinical Study
us.rd.yahoo.com - March 17 at 12:13 AM
biz.yahoo.com logoSERES THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure,
us.rd.yahoo.com - March 17 at 12:13 AM
bizjournals.com logoSeres gets FDA mulligan on microbiome drug, eyes pivotal trial
us.rd.yahoo.com - March 17 at 12:13 AM
thestreet.com logoBiotech Premarket Movers: Seres, PTC, Inovio
us.rd.yahoo.com - March 17 at 12:13 AM
fool.com logoHere's What's Lifting Seres Therapeutics Inc.'s Stock Price Today
www.fool.com - March 16 at 1:47 PM
biz.yahoo.com logoSeres Therapeutics Inc Earnings Call scheduled for 8:00 am ET today
biz.yahoo.com - March 16 at 4:45 AM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Receives Consensus Rating of “Buy” from Brokerages
www.americanbankingnews.com - March 15 at 11:36 AM
finance.yahoo.com logoSeres Therapeutics to Host Fourth Quarter 2016 Financial Results and Operational Progress Conference Call and Webcast on March 16, 2017
finance.yahoo.com - March 13 at 10:25 AM
americanbankingnews.com logoSeres Therapeutics Inc (MCRB) Sees Significant Decrease in Short Interest
www.americanbankingnews.com - March 13 at 8:23 AM
finance.yahoo.com logoSeres Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 2 at 9:39 AM
finance.yahoo.com logoWhy Seres Therapeutics (MCRB) Might Surprise This Earnings Season
finance.yahoo.com - March 1 at 10:59 AM

Social

Chart

Seres Therapeutics (MCRB) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by MarketBeat.com Staff